{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:15:42Z","timestamp":1780380942451,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12105-021-01305-9","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T16:05:10Z","timestamp":1614009910000},"page":"1399-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass"],"prefix":"10.1007","volume":"15","author":[{"given":"Amy S.","family":"Duffield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius S.","family":"Necciai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"McCuiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-3375","authenticated-orcid":false,"given":"Alisha D.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"issue":"2","key":"1305_CR1","first-page":"119","volume":"8","author":"J Mangini","year":"2000","unstructured":"Mangini J, Silverman JF, Dabbs DJ, Tung MY, Silverman AR. Diagnostic value of calretinin in mast cell lesions of the skin. Int J SurgPathol. 2000;8(2):119\u201322.","journal-title":"Int J SurgPathol"},{"issue":"5","key":"1305_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/DAD.0b013e31823aded5","volume":"34","author":"E Gonz\u00e1lez-Guerra","year":"2012","unstructured":"Gonz\u00e1lez-Guerra E, Kutzner H, Rutten A, Requena L. Immunohistochemical study of calretinin in normal skin and cutaneous adnexal proliferations. Am J Dermatopathol. 2012;34(5):491\u2013505.","journal-title":"Am J Dermatopathol"},{"issue":"13","key":"1305_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"6","key":"1305_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","volume":"21","author":"G Metzgeroth","year":"2007","unstructured":"Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183\u20138.","journal-title":"Leukemia"},{"key":"1305_CR5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised. 4th ed. Lyon Cedex 08: International Agency for Research on Cancer IARC; 2017.","edition":"4"},{"issue":"3","key":"1305_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.iac.2007.06.001","volume":"27","author":"BJ Bain","year":"2007","unstructured":"Bain BJ, Fletcher SH. Chronic eosinophilicleukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin N Am. 2007;27(3):377\u201388.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"4","key":"1305_CR7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.leu.2403313","volume":"18","author":"P Vandenberghe","year":"2004","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, Zach\u00e9e P, Boogaerts M, Vanstraelen D, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilicleukemias. Leukemia. 2004;18(4):734\u201342.","journal-title":"Leukemia"},{"issue":"6","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704\u201314.","journal-title":"Blood"},{"issue":"6","key":"1305_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemianet. Blood. 2006;108(6):1809\u201320.","journal-title":"Blood"},{"issue":"5","key":"1305_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","volume":"143","author":"G Metzgeroth","year":"2008","unstructured":"Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, et al. Safety and efficacy of imatinib in chronic eosinophilicleukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008;143(5):707\u201315.","journal-title":"Br J Haematol"},{"issue":"10","key":"1305_CR11","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","volume":"110","author":"AD Klion","year":"2007","unstructured":"Klion AD, Robyn J, Maric I, Fu W, Schmid L, Lemery S, et al. Relapse following discontinuation of imatinibmesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007;110(10):3552\u20136.","journal-title":"Blood"},{"issue":"9","key":"1305_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, et al. The efficacy of imatinibmesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome results of a multicenter prospective study. Haematologica. 2007;92(9):1173\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"1305_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/ajh.23588","volume":"89","author":"G Helbig","year":"2014","unstructured":"Helbig G, Kyrcz-Krzemie\u0144 S. Cessation of imatinibmesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Am J Hematol. 2014;89(1):115.","journal-title":"Am J Hematol"},{"issue":"4","key":"1305_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","volume":"121","author":"D Simon","year":"2008","unstructured":"Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy ClinImmunol. 2008;121(4):1054\u20136.","journal-title":"J Allergy ClinImmunol"},{"issue":"2","key":"1305_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/sj.leu.2403600","volume":"19","author":"N von Bubnoff","year":"2005","unstructured":"von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005;19(2):286\u20137.","journal-title":"Leukemia"},{"issue":"5","key":"1305_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/leu.2009.2","volume":"23","author":"E Lierman","year":"2009","unstructured":"Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23(5):845\u201351.","journal-title":"Leukemia"},{"issue":"4","key":"1305_CR17","first-page":"282","volume":"42","author":"I Sadovnik","year":"2014","unstructured":"Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, et al. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. ExpHematol. 2014;42(4):282-93.e4.","journal-title":"ExpHematol"},{"issue":"9","key":"1305_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","volume":"126","author":"AD Klion","year":"2015","unstructured":"Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126(9):1069\u201377.","journal-title":"Blood"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-021-01305-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01305-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T06:37:03Z","timestamp":1638340623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-021-01305-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s12105-021-01305-9","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"24 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors declare that they have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript constitutes a retrospective analysis of one clinical case (a \u201ccase report\u201d). The Johns Hopkins Medicine Institutional Review Board does not require review of case reports, as case reports do not meet the Department of Health and Human Services definition of \u201cresearch\u201d (). HIPAA identifiers (including unique patient characteristics) are not included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Consent for publication was verbally obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}